The study was designed to only look at pre- and immediate post-operative IFABP, and did not look at ongoing IFABP levels, which would help better establish the temporal relationship between serum IFABP and NEC, as well as its potential utility as a point-of-care biomarker. The gene discussed is FABP2; the disease is necrotizing enterocolitis.